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Abstract. Recurrent differentiated thyroid carcinoma can 
easily be detected by means of ultrasound (US) and thyro-
globulin, and often requires further surgical intervention. 
Revision surgery is often a technical challenge with significant 
risk of complications, considering the altered anatomy, with a 
possibility of leaving behind residual neoplasm. Preoperative 
US-guided tattooing localization has been introduced to reduce 
and prevent these potential problems during revision surgery. 
Encouraging results have been reported in the literature. 
Under US guidance, the lesion is identified and 0.5‑2 ml of 
colloidal charcoal is injected in its proximity using a 23 gauge 
needle. The extraction is accompanied by injection at constant 
pressure of charcoal in order to leave a trace of pigment 
along the path of the needle till the skin. From April 2008 to 
January 2016 we performed revision surgery in 27 patients for 
lymph-nodes metastasis in differentiated thyroid cancer, using 
the technique of preoperative charcoal tattoo localization. Our 
previous study on the first group of 13 patients published in 
2012, reported the preliminary results in terms of success rate 
and complications. The tolerance of charcoal injection was 
good for all patients and the procedure was demonstrated to be 
useful, contributing to the removal of metastatic lesion in 93% 
of procedures. We have registered minor surgical complica-
tions during revision in the central compartment of the neck: 
Transitory hypoparathyroidism in 2 cases (11%) and transitory 
vocal cord paresis in 3 cases (16%). Based on these results, 
preoperative charcoal tattoo localization in revision surgery 
of the neck for differentiated thyroid cancer recurrence can be 
considered a safe technique, easy to perform, with low-costs 
and useful during surgical procedures, providing a significant 
reduction of iatrogenic damage and risks.
Introduction
5 to 40% of patients treated for differentiated thyroid cancer 
(DTC) can be affected by persistent or recurrent disease (1). 
Treatment with radioiodine alone, in a significant number 
of cases, is able to completely eliminate tumor recurrence. 
Nevertheless, up to 30% of tumors will not show 131I uptake. In 
these cases, a surgical management of the lesion is required (2). 
During revision surgery, a significant number of intraoperative 
complications can occur, especially in the central compart-
ment of the neck. Alteration of the normal anatomy, fibrosis 
and scar tissue formation in the neck makes identification and 
preservation of the recurrent laryngeal nerves and parathyroid 
glands difficult (3). Another aspect to consider during revision 
surgery is the achievement of oncologic radicality. Recurrent 
laryngeal nerves and parathyroids may be encased in fibrotic 
tissue, making them indistinguishable from pathologic tissue. 
There is a considerable high risk of leaving residual neoplasm 
in the field (4).
In order to simplify localization and excision of neoplastic 
foci during revision surgery for DTC recurrence, we have 
employed a new technique of preoperative ultrasound-guided 
tattooing (US-tattoo) for the detection of the structures to 
be removed, likewise to the US-tattoo technique routinely 
applied in patients affected by breast cancer for more than 
15 years (5). To date this procedure is supported by only four 
4 studies reporting encouraging results (2,3,6,7). The first 
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13 patients have been reported in our previous article where 
the preliminary results have been reported in terms of success 
rate and complications (7).
In this study, we report our overall experience with the 
technique of fine‑needle injection of charcoal pigment under 
US guidance for localization, and consequent surgical excision 
of DTC lymphatic metastasis in the neck.
Materials and methods
This was a retrospective analysis, performed in the Head and 
Neck Department, Ear Nose and Throat (ENT) Unit of Santa 
Maria delle Croci Hospital, Ravenna, Italy. All procedures 
performed in this study involving human participants were 
in accordance with the ethical standards of the institutional 
and/or national research committee, and with the 1964 
Helsinki declaration and its later amendments or comparable 
ethical standards. The study was designed and conducted in 
compliance with the principles of Good Clincal Practice regu-
lations and the Helsinki declaration. Written informed consent 
was obtained from patients before inclusion in this study.
From April 2008 to January 2016, a prospective study 
was conducted on patients who previously underwent surgical 
treatment for DTC, and thereafter presented to our centre 
with a suspected DTC recurrence in the neck. The initial 
operation and pTNM classification are shown in Table I. Vocal 
folds motility by videofiberoptic endoscopic assessment and 
parathyroid function was preoperatively verified. Radioiodine 
treatment was administered after surgical treatment in all 
patients population, except for one.
Recurrence or suspicious lesions discovered during 
follow-up, by means of US and TSH-stimulated Tg determi-
nation were investigated by cytology (FNA), in association 
with Tg determination in the washout of fine needle aspiration 
(FNAB-Tg), following the TI-RADS criteria (8). Recurrent 
lesions have been detected both in central and lateral compart-
ment of the neck. In order to perform a super-selective neck 
dissection around the metastatic node, suspicious metastatic 
lymph-nodes in the lateral groups are also marked (2,3,6). 
Informed consent was obtained from all patients.
A suspension of active charcoal 80 mg/2 ml (4%), commonly 
used for tattooing breast cancer lesions, was used (composi-
tion: active charcoal 80 mg + Polysorbate-80 80 mg + water 
for injectable preparations to reach 2 ml). Before aspiration 
and injection, the charcoal vial is heated by keeping it between 
the operator hands for a few minutes. This is done to prevent 
blockage of the needle tip by charcoal particles. The lesion is 
identified under US guidance; US imaging is performed using 
a machine with multi-frequency probe (7-12 MHz Esaote 
MyLab 70).
After identification, a 23‑gauge needle is inserted near 
the suspected lesion, since we prefer to avoid injecting inside 
the lesion so as not to compromise histological examina-
tion. At this point we can proceed with injection of 0.5-2 ml 
of charcoal by means of a 5 ml syringe. The amount to be 
injected depends on the depth of the lesion. In proximity of the 
suspected neoplasm, a store of colouring which we define as 
charcoal ‘puddle’ takes form (Fig. 1). Extraction of the needle 
is accompanied by an injection at constant pressure of the 
charcoal in order to leave a trace of colouring along the way 
of the needle till the skin, where a tattoo resembling a little 
nevus will persist for some weeks. This last step provided a 
valid indication about the direction to follow during surgical 
operation, in order to reach the suspected metastatic lesion.
This procedure can be performed from just a few days 
to some weeks before surgery, as it has been demonstrated 
that charcoal remains in place for at least 3 months after 
injection (9,10). Charcoal injection is performed in the 
Endocrinology unit as an ambulatory setting. The patient can 
return home after at least 20 min of observation. The patient 
is advised to rest, avoid in particular bending the neck and 
the head, and raising heavy loads after the procedure. In case 
of soreness or pain in the area of needle insertion, the use 
of a common analgesic is recommended. Only a descriptive 
analysis has been performed.
Results
A total number of 27 patients (20 females and 7 males) with an 
average age of 46 years (range, 25-73 years) presented to our 
centre (1 of them was initially treated in another hospital) with 
a suspected DTC recurrence in the neck (Table I). The average 
time of recurrence was 19 months (range, 3-84 months). 
Preoperative injection was well tolerated in all cases with 
patients complaining of the same mild discomfort of a FNA, 
experienced previously by all of them. No complications 
related to the procedure of US-tattooing were observed.
In the last 93 months (April 2008-January 2016) we have 
re-operated 27 patients with suspected metastatic lesion 
of DTC using the technique of US-tattoo localization. The 
primary cancer was always papillary carcinoma (with Warthin 
like aspects in 1 case, no. 22). Immediately prior to surgery in 
the operating room, we perform another US examination to 
have a better conception of the metastatic lesion and to define 
its anatomical relation. All the operations were performed by 
the same expert surgeon (FS and ADV). To recognize neural 
structures and assess their functionality we made use during 
surgery of Bovie Neuro-Pulse™ surgical nerve locator.
For the 16 cases the target was a suspected level VI node 
(nos. 2, 3, 5-8, 12-16, 18-21) (Table I; Fig. 2).
The first operation was a total thyroidectomy in 4 cases, 
thyroidectomy with dissection of level VI in 7 cases, and 
thyroidectomy with dissection of level VI in associated with 
selective neck dissection in 5 cases (Table I). The re-operation 
for these patients consisted of level VI dissection (compre-
hensive of the marked node) in 3 cases, revision of level VI 
dissection in 13 cases; number of nodes removed in central or 
lateral compartment is reported in Table I. For patients firstly 
not undergone central compartment lymphadenectomy, the use 
of charcoal tattoo is of great importance to assure inclusion of 
the suspected node in the dissection.
In patients already submitted to central compart-
ment dissection, the operation consisted of removal of the 
charcoal-localized node possibly associated with fatty or 
connective tissue (suspected of containing other lymphatic 
nodes) surrounding the targeted lesion. In four patients, 
cytology was not suggestive of a definitive diagnosis. However, 
on the basis of US aspects and TG determination, we proceeded 
to perform revision surgery and metastatic lesion was found in 
2 cases (nos. 12 and 16), in the other one a metastatic lesion 
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was found associated with parathyroid cyst (no. 6) and finally 
the suspected lesion, which is of small dimension (3 x 5 mm), 
were not confirmed at histological examination, even if a 
group of 3 nodes were removed (no. 20).
The last was the unique case in our experience we did not 
observe any trace of charcoal in proximity of the suspected 
lesion during the surgical operation. We found colouring 
traces just in the first layer of dissection (skin, subcutaneous 
and scar tissue), which is of poor usefulness for our surgical 
aim. Similar to what occurred in case no. 20, in patient no. 18 
the metastatic node was not found despite the removal of three 
nodes around the coal deposit (Table I). For these patients, 
considering the small size of the lesion together with objec-
tive surgical difficulties, we decided for a further radioiodine 
treatment followed by close controls and reoperation in case of 
volumetric increase of the lesion.
After revision surgery in the central compartment, we 
observed minor complications in 5 cases: 2 patients suffered 
temporary hypoparathyroidism (solved with medical therapy) 
and 3 experienced temporary recurrent nerve paralysis. In a 
subset of 9 patients (patients nos. 1, 9-11 and 23-27) we marked 
exclusively lesions in lateral compartment of the neck. In one 
case (no. 26) 2 distinct marks were performed and in 1 of 
these, in the level II area, we observed a widespread diffu-
sion of charcoal. In all other cases we could follow the trace 
created during extraction of the needle, and found the charcoal 
injected quite localized on the suspected lesion and therefore 
useful for surgical manoeuvres (Fig. 3).
The histological examination has given a favourable 
outcome, confirming the removal of metastatic lesion in all 
cases. No complications related to lateral neck dissections 
were registered.
In case no. 4 and no. 22, we performed a double marking 
of a lesion localized in VI area and another respectively in 
level III and IV (dorsal to jugular vein). Removal of metastatic 
lesion was obtained in both cases with no registration of 
surgical complications. Considering overall results, metastatic 
lesions were found in 25 out of 27 patients (92%) (Table I). 
Follow up with US and Tg determination of at least 6 months 
confirmed the positive outcome of surgery.
Discussion
DTC is the most common endocrine tumour. Despite the 
increase in the number of cases in recent years, its course is 
favourable with a survival rate of 10 years till 90%, and its inci-
dence in all deaths for neoplastic diseases is at only 0,5% (11). 
Lymphatic metastasis of DTC has been considered, until a 
short time ago of negligible importance for the prognosis. 
Various studies have reported percentages of survival rates of 
10 years till 95% for papillary carcinoma, and till 70% for the 
follicular variant (12-16). Recently, however, major attention is 
placed on the concept of ‘disease free survival’ considering, in 
spite of high values of survival, the not negligible incidences of 
disease recurrence (15-35% also to 20 years), with a meaningful 
impact on the quality of life (due to the necessity of surgical 
reoperations and/or of elevated doses of radioiodine) (17,18).
The incidence of DTC recurrence after thyroidectomy has 
increased with the routine employment of ultrasound (US) and 
thyroglobulin (Tg). Revision surgery in the neck for recur-
rent/persistent DTC is associated with increased morbidity 
compared with primary surgery because of the presence of scar 
tissue and disruption of the normal fascial planes and anatomy. 
This may result in a greater risk of injury to nerves and other 
important anatomical structures (19). These concepts are valid 
especially for area VI surgical revision. In spite of every thera-
peutic attitude regarding the N0 necks in DTC, re-operations 
Figure 1. Ultrasound performed just before surgery showing the localization 
of the lymph node, anatomical associations and the accumulation of charcoal.
Figure 2. Traces of charcoal near a suspected node during area 6 revision 
surgery.
Figure 3. Accumulation of charcoal near the level IV node and in the previous 
needle path providing the direction to follow during dissection. The arrow 
indicates the charcoal trace created during needle extraction.
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in the central compartment may be necessary, even when it has 
been performed during the first operation. In fact, radicality 
is very difficult to obtain, especially for nodes situated on the 
superior edge of mediastinal space. Risk of damaging laryn-
geal nerves can reach 20% (ranging from 0.7 to 4.5% during 
first operation) and risk of hypoparathyroidism can increase to 
30% (ranging from 8 to 13% in primary procedures) (20,21).
Even though our study consists of a small number of 
treated patients, we observed a transitory hypoparathyroidism 
in 2 cases (11% if we consider only 18 cases of area 6 revi-
sion) and a transitory vocal cord paresis in 3 (16% referring 
exclusively to area 6 revision). No damages of important 
anatomical structures were registered during lateral neck 
dissection. Greater morbidity during central compartment 
revision is related to difficulties in identification and preserva-
tion of recurrent laryngeal nerves and parathyroid glands. To 
prevent recurrent nerve injuries, it is possible to make use of 
intraoperative neurological monitoring and/or rely on some 
surgical tricks such as identification of each nerve low in the 
tracheoesophageal groove, distant from the thyroid bed and 
the use of meticulous surgical dissection from inferior to supe-
rior (4). In order to preserve the function of the parathyroid 
glands, devascularisation should be prevented. The inferior 
thyroid artery should be respected (4).
The gold standard for revision surgery should be a reli-
able procedure to guide revision surgery. To date the most 
common intraoperative procedure is the use of a gamma 
probe. Efficacy of this technique however can be limited by 
false negative and false positive findings. It is only useful 
in cases of radioiodine-avid foci (22-24). Other modalities 
such as intraoperative US exploration hook needle inser-
tion or tattooing using blue dye have also been described. 
However, their efficacy, safety and feasibility are not well 
demonstrated (25-27). Other radio guided methods as well as 
other radiotracers such us FDG were recently developed for 
the intraoperative guidance of non-radioiodine avid cancer, 
but cost, availability and signal-to-noise issues may limit their 
widespread use (28-30).
Despite all these procedures, revision surgery of central 
compartment dissection remains difficult even in expert hands. 
Given this context, the US-tattoo localization technique can 
represent an instrument of considerable usefulness (2,3,6,7).
Active charcoal for its physical and pharmacological 
properties, which ensure limited diffusion and good stability, 
is the ideal substance for marking of target in soft tissues. In 
our experience this technique has been of significant utility 
in identifying metastatic lesions during revision surgery in a 
great majority of cases (93%). In a total of 30 procedures, we 
registered only in 1 case an unexplained absence of coal and 
in a further one, an excessive widespread in the surgical field. 
Furthermore, this technique, executable even several week 
before surgery, is easy to implement and at a very low cost. 
Finally, another aspect of great importance is the good toler-
ability and the complete absence of complications related to 
the procedure.
In conclusion, based on our experience we can suggest 
that US-tattoo localization of lymphatic neck metastasis of 
DTC is a safe technique, of low cost and extremely useful in 
facilitating surgical procedures, especially in difficult revi-
sion surgery of the neck. This technique allows risk reduction 
of iatrogenic complications, especially of the parathyroid 
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